Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase 3 6Phase 1/2 4Phase NA 1Phase 4 1Phase 1 1

Status

Active not recruiting 5Recruiting 4Completed 4Terminated 3Withdrawn 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Lymphoma, Mantle-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Capecitabine 27Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × acalabrutinib × Clear all
NCT06564038 2026-05-14

Soundtrack-E

AstraZeneca

Phase 1/2 Recruiting
408 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT05256641 2026-03-10

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Jonsson Comprehensive Cancer Center

Phase 1/2 Recruiting
24 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04855695 2026-01-21

Avo In R/R And Previously Untreated MCL

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
72 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡